NCT02629692 2024-07-31Safety and Anti-leukemic Activity of Vodobatinib (K0706) for Treatment of Ph+ CML Resistant/Intolerant to ≥3 Prior CML TherapiesSun Pharma Advanced Research Company LimitedPhase 1/2 Active not recruiting122 enrolled